High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib.
appalumbo@yahoo.com.
Manuela
M
Gambella
Alberto
A
Rocci
Roberto
R
Passera
Francesca
F
Gay
Paola
P
Omedè
Claudia
C
Crippa
Paolo
P
Corradini
Alessandra
A
Romano
Davide
D
Rossi
Marco
M
Ladetto
Mario
M
Boccadoro
Antonio
A
Palumbo
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D014408:Biomarkers, Tumor / Q000096:biosynthesis*; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D004268:DNA-Binding Proteins / Q000096:biosynthesis*; D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D011719:Pyrazines / Q000008:administration & dosage*; D000071701:Regulatory Factor X Transcription Factors; D015996:Survival Rate; D014157:Transcription Factors / Q000096:biosynthesis*; D000071717:X-Box Binding Protein 1
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D001897:Boronic Acids; D004268:DNA-Binding Proteins; D009363:Neoplasm Proteins; D011719:Pyrazines; D000071701:Regulatory Factor X Transcription Factors; D014157:Transcription Factors; D000071717:X-Box Binding Protein 1; C000605543:XBP1 protein, human; D000069286:Bortezomib
BLIMP1; IRF4; XBP1; bortezomib; multiple myeloma biomarker